Research programme: oral biological cocktail - Lumen Bioscience
Latest Information Update: 29 Nov 2025
At a glance
- Originator Lumen Bioscience
- Class Anti-inflammatories; Uricosurics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Crohn's disease; Ulcerative colitis; Urinary calculi
Most Recent Events
- 08 Aug 2025 Lumen Bioscience plans phase I trial in Crohn's disease and Ulcerative colitis in 2025 (Lumen Bioscience pipeline, August 2025)
- 08 Aug 2025 Lumen Bioscience plans phase II/III second pivotal trial in Urinary calculi in 2025 (Lumen Bioscience pipeline, August 2025)
- 31 Dec 2021 Preclinical trials in Crohn's disease in USA (unspecified route), before August 2025 (Lumen Bioscience pipeline, August 2025)